Brain Scientific Inc. (BRSF) E-Tattoo Will Offer AI Solutions for Neurology

February 2, 2021 15:10:18
  • BRSF paving way with next wave of innovation for neurology: e-tattoos
  • Acceptance of telemedicine, AI here to stay following pandemic
  • Scientists have learned how to read brain waves using minimally invasive, implantable, four-channel micro EEG to better monitor continuous seizures

The COVID-19 pandemic has accelerated several changes to American culture, many of which appear to be here to stay. According to Harvard experts, some of those changes include movement towards a cashless society, increased remote work, the decline of brick-and-mortar retail, and a new approach to health that includes an acceptance of telemedicine and artificial intelligence (“AI”) (https://ibn.fm/f9IJ5). Brain Scientific (OTCQB: BRSF) is positioned to benefit from that growing acceptance of AI as it focuses on modernizing brain diagnostics.

Early in 2020, Elon Musk announced work on brain interface tech to turn humans into a genius super race. While Musk grabs the spotlight for all things high tech, his brain-computer chip company Neuralink went down as one of many overhyped AI ideas for the year (https://ibn.fm/E9mtr). Musk’s idea might sound like science fiction, allowing an external computer to input data as though the mind is nothing more than a computer processor, but the reverse is a reality.

Elon Musk has dreams of fixing anything wrong with the brain, but before that can be achieved, the problem first needs to be identified and understood. Currently, scientists are working to understand what causes Parkinson’s disease, Alzheimer’s disease, dementia and other neurological issues. The root of the problem must be discovered before the solution is created.

The good news is that BRSF is making inroads in helping identify those problems. The company has unveiled a new initiative to develop a brain E-Tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes would be connected to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. Each patient’s data is secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis. This provides 24/7 uninterrupted seizure monitoring, something that was unavailable previously with the bulky EEGs administered and overseen by specialized techs in hospitals.

The EEG dates back to 1929 and has only seen drastic advances in the last few decades. “COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, co-founder and executive chairman at BRSF (https://ibn.fm/kP4jX). “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology.

“The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions,” he continued. “Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life. While we aren’t yet ready as a society to cyborg our way past neurological issues, we are on the cusp of better understanding and diagnosing them. Thanks to cutting-edge technology like BRSF’s e-Tattoo, answers are right around the corner.”

BRSF is committed to modernize brain diagnostics through cutting edge technologies that narrow the widening gap of accessibility to much needed neurological care. In addition to its e-tattoo innovation, the company has received FDA clearance for two transformative EEG products — the NeuroCap(TM) and NeuroEEG(TM) —  that have the potential to disrupt the market, provide EEG accessibility and 24/7 EEG coverage where it was once unavailable.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.